Is Your Child's Allowance Undermining Your Retirement?
The $1,000 Challenge, Part 9: Nibbling Away at the Family Food Bills
The Benefits of Filing Your Taxes Early
Judge: Ex-Goldman Trader 'Fabulous Fab' to Pay $825,000
Is Celgene the Perfect Stock?
Merck has confirmed that it halted its late-stage student of vorapaxar, a potential clot-preventing drug, after an increased risk of bleeding in some patients.